Page 5 - Daniel Drucker News Today

Because Ozempic mimics a natural gut hormone in our bodies, increasing this hormone should provide similar benefits, but to what extent?

Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for dasiglucagon in CHI in 2023 and solid financial position Boehringer Ingelheim advances GCGR/GLP-1R dual agonist survodutide (BI456906) into Phase 3 trials in obesityZealand presents amylin analog ZP8396 6-week trial results at ObesityWeek and initiates GLP-1R/GLP-2R dual agonist dapiglutide 13-week dose titration trialZeal

How inadequate funding for research and messy innovation policy ripples out to the economy and society

Recent studies evaluate risks associated with drugs such as Wegovy and Mounjaro

Recent studies evaluate risks associated with drugs such as Wegovy and Mounjaro. Recent studies evaluate risks associated with drugs such as Wegovy and Mounjaro.

Companies from Walmart Inc. to Conagra Brands Inc. are weighing how much to factor the diabetes drugs known as GLP-1s, increasingly being used for weight loss, into their strategies.

Reactions by companies like Walmart and Conagra could reverberate for years, so the pressure’s high to get it right.

Companies are weighing how much to factor the diabetes drugs increasingly being used for weight loss into their strategies.

This past week in healthcare investigations

The sucker-like device is a cheeky way to take your medicine.